Numerous studies have identified ARID1A as a bona fide tumor suppressor during the oncogenic process, and its downregulation and mutations have been frequently reported in a broad spectrum of cancers (8), including gastrointestinal tract tumors (9-11). This evidence concerns the gene ARID1A and neoplasm.